KALA
KALA BIO, Inc.
Key Financials
Revenue
$0
NaN%
Net Income
$-26980000
↑ 29.9%
Operating Income
$-39161000
↑ 4.4%
Total Assets
$9.5M
↓ 82.9%
Total Liabilities
$2.5M
↓ 94.2%
EPS (Diluted)
$-3.31
↑ 67.4%
Cash & Equivalents
$7.6M
↓ 85.2%
Long-term Debt
$29.3M
↓ 32.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| NT 10-Q | 8/14/2026 | View on SEC |
| 8-K | 7/23/2026 | View on SEC |
| 424B5 | 7/22/2026 | View on SEC |
| SCHEDULE 13D/A | 7/2/2026 | View on SEC |
| EFFECT | 6/25/2026 | View on SEC |
| S-3/A | 6/12/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
| S-3 | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KALA |
| Company Name | KALA BIO, Inc. |
| CIK | 1479419 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 781-996-5252 |